Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 6/20 | 0.44 |
| ▸ | AHCY | P23526 | 1/20 | 0.43 |
| ▸ | PGK1 | P00558 | 1/20 | 0.42 |
| ▸ | PGK2 | P07205 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19236305 | 1.00 | CYP2C19 (0.47) | CYP2C19ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL10268842 | 0.89 | CYP2C19 (0.44) | CYP2C19ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL15628203 | 0.89 | CYP2C19 (0.44) | CYP2C19ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL1287306 | 0.89 | CYP2C19 (0.44) | CYP2C19ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL18636243 | 0.89 | CYP2C19 (0.44) | CYP2C19ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL10268734 | 0.89 | CYP2C19 (0.44) | CYP2C19ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL22036934 | 0.88 | CYP2C19 (0.53) | CYP2C19ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL8621051 | 0.88 | NT5E (0.47) | CYP2C19ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL8621057 | 0.88 | NT5E (0.47) | CYP2C19ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL20633580 | 0.87 | CYP2C19 (0.42) | CYP2C19ADORA3ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | GILEAD PHARMASSET LLC (US) | 2018-10-16 | — | — | US | disclosed |
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | GILEAD SCIENCES, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| EP-2251015-B1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | GILEAD PHARMASSET LLC (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PHARMASSET, INC. | 2011-11-03 | — | — | US | disclosed |
| EP-2251015-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | Pharmasset, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | PHARMASSET, INC. | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | SLC29A1, PNP, SLC29A2 | CYP2C19 265/4885ADORA3 83/4885ADORA1 231/4885 |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PNP, ALPP, XDH | CYP2C19 546/4885ADORA3 160/4885ADORA1 254/4885 |
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, SLC29A2, PNP | CYP2C19 492/4885ADORA3 61/4885ADORA1 111/4885 |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, PNP, SLC29A2 | CYP2C19 337/4885ADORA3 82/4885ADORA1 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.